Swartz Robin 4

What Happened
Robin Swartz, Chief Operating Officer & Chief Business Officer of Voyager Therapeutics (VYGR), was granted two awards on February 6, 2026: 45,000 restricted stock units (RSUs) and a 210,000-share stock option (reported as a derivative). Both grants are reported at $0.00 (i.e., awarded as compensation), not purchases or sales.

Key Details

• Transaction date: February 6, 2026; reported on Form 4 filed February 10, 2026 (filed within the typical two-business-day window).
• Price: $0.00 for both the RSU award and the option grant (reported value $0).
• Shares owned after transaction: Not specified in the filing provided.
• Footnote highlights:
  • F1 (RSUs): 45,000 RSUs; each RSU converts to one share upon vesting. Vesting starts on the grant date (2/6/2026) and occurs over three years — 1/3 vests on the one-year anniversary, then 1/3 each year thereafter, subject to continued service.
  • F2 (Option): 210,000-share stock option; vesting starts on the grant date (2/6/2026) and vests over four years on a monthly schedule (1/48th vests after one month, then monthly thereafter), subject to continued service.
• No indication of tax withholding, 10b5-1 plan, cashless exercise, or immediate sale in this filing.

Context
RSUs and stock options are common forms of executive compensation. RSUs convert to shares when they vest; options must be exercised (and may have an associated strike price not shown here) to become shares. These awards are compensation-related grants rather than open-market purchases or sales, so they primarily reflect company compensation decisions rather than an immediate insider buy/sell signal.